EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metastatic Recurrence of Breast Cancer by Stage and Molecular Profile: A Population‐Based Study Among Italian Women

Fabiola Giudici iD, Sara De Vidi, Stefano Guzzinati, Federica Toffolutti, Silvia Francisci, Angela B Mariotto, Alessandra Ravaioli, Laura Botta iD, Roberta De Angelis, Ettore Bidoli, Fabio Falcini, Antonella Puppo und 9 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.71492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Fabiola Giudici und 20 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute, Fondazione AIRC per la ricerca sul cancro ETS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aims to estimate the long‐term risk of metastatic recurrence (MR) among Italian women with breast cancer (BC) by period, age, stage, and surrogate molecular profile.

Methods

Data on 59,968 women below age 75 years diagnosed in 1997–2017 with stage I‐III BC from 7 population‐based Italian cancer registries were analyzed. We used a novel modeling method, based on an illness–death process coupled with a mixture cure model, to estimate relative survival and MR risks up to 15 years after BC diagnosis according to calendar period, age, stage, and profile.

Results

The risk of MR for the entire cohort at 15 years decreased from 20.6% in 1997–2006 to 12.3% in 2007–2017, when MR risk within 15 years was 3.0% for stage I, 16.0% for stage II, and 42.7% for stage III. The conditional risk of MR decreased with time since diagnosis, with stage I–III triple‐negative BC having a higher risk of developing MR in the first 5 years regardless of age (16.0% at age 15–54 years and 18.3% at 55–74 years), but < 1% once they survived for 5 years without recurrence. In contrast, hormone receptor‐positive BC had a lower but persisting risk of MR of about 6% for both age groups in the first 10 years, halving to about 3% in the following 5 years after diagnosis.

Conclusions

This study provides a population‐based estimate of the long‐term risk of MR for women with BC by major prognostic factors. These findings may help in tailoring follow‐up strategies through informative risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm Recurrence, LocalHumansFemaleMiddle AgedItalyAdultAgedNeoplasm StagingYoung AdultAdolescentRegistriesNeoplasm MetastasisRisk FactorsAge FactorsBiomarkers, Tumor

Stichwörter der Autor:innen

breast cancermetastatic recurrencemixed cure modelrelative survival

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Epidemiological Department, Azienda Zero, Padua, Italy.
  • National Centre for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy.
  • Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
  • Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Forlì, Italy.
  • Evaluative Epidemiology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

ORCID-Profile: Fabiola Giudici, Laura Botta, Riccardo Capocaccia, Luigino Dal Maso

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • Ministero della Salute
  • Fondazione AIRC per la ricerca sul cancro ETS

Zitieren

APA

Giudici, F., De Vidi, S., Guzzinati, S., Toffolutti, F., Francisci, S., Mariotto, A. B., Ravaioli, A., Botta, L., De Angelis, R., Bidoli, E., Falcini, F., Puppo, A., Mangone, L., Michiara, M., Fusco, M., Fanetti, A. C., Andreotti, A., Capocaccia, R., Serraino, D., …, & AIRTUM working group (2026). Metastatic Recurrence of Breast Cancer by Stage and Molecular Profile: A Population‐Based Study Among Italian Women. Cancer Medicine. https://doi.org/10.1002/cam4.71492

Vancouver

Giudici F, De Vidi S, Guzzinati S, Toffolutti F, Francisci S, Mariotto AB, et al. Metastatic Recurrence of Breast Cancer by Stage and Molecular Profile: A Population‐Based Study Among Italian Women. Cancer Medicine. 2026. doi:10.1002/cam4.71492

BibTeX
@article{Giudici2026,
  author = {Giudici, Fabiola and De Vidi, Sara and Guzzinati, Stefano and Toffolutti, Federica and Francisci, Silvia and Mariotto, Angela B and Ravaioli, Alessandra and Botta, Laura and De Angelis, Roberta and Bidoli, Ettore and Falcini, Fabio and Puppo, Antonella and Mangone, Lucia and Michiara, Maria and Fusco, Mario and Fanetti, Anna Clara and Andreotti, Alessandra and Capocaccia, Riccardo and Serraino, Diego and Dal Maso, Luigino and AIRTUM working group, AIRTUM working group},
  title = {Metastatic Recurrence of Breast Cancer by Stage and Molecular Profile: A Population‐Based Study Among Italian Women},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71492}
}
Kostenlos starten →